Charles Schwab Investment Management Inc. Grows Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Charles Schwab Investment Management Inc. grew its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 916,743 shares of the company’s stock after buying an additional 10,262 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Adaptive Biotechnologies were worth $4,694,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. JTC Employer Solutions Trustee Ltd bought a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new position in shares of Adaptive Biotechnologies in the 3rd quarter worth approximately $34,000. MQS Management LLC bought a new position in shares of Adaptive Biotechnologies in the 2nd quarter worth approximately $36,000. Rothschild Investment LLC bought a new position in shares of Adaptive Biotechnologies in the 2nd quarter worth approximately $36,000. Finally, Nisa Investment Advisors LLC raised its position in shares of Adaptive Biotechnologies by 769.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 13,392 shares of the company’s stock worth $48,000 after acquiring an additional 11,852 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Trading Up 2.3 %

Shares of ADPT stock opened at $6.30 on Friday. Adaptive Biotechnologies Co. has a 12-month low of $2.28 and a 12-month high of $7.07. The stock’s 50-day moving average price is $5.37 and its 200-day moving average price is $4.57. The stock has a market capitalization of $929.75 million, a price-to-earnings ratio of -4.70 and a beta of 1.49.

Analyst Ratings Changes

ADPT has been the subject of a number of analyst reports. Piper Sandler raised their price objective on Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. BTIG Research lifted their target price on Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.